ATRIPLA Drug Patent Profile

When do Atripla patents expire, and when can generic versions of Atripla launch?

Atripla is a drug marketed by Gilead Sciences and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in twenty-seven countries.

The generic ingredient in ATRIPLA is efavirenz; emtricitabine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Atripla

Atripla was eligible for patent challenges on July 2, 2007.

There have been twenty-two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (efavirenz; emtricitabine; tenofovir disoproxil fumarate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ATRIPLA

International Patents:	61
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	54
Patent Applications:	84
Drug Prices:	Drug price information for ATRIPLA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ATRIPLA
What excipients (inactive ingredients) are in ATRIPLA?	ATRIPLA excipients list
DailyMed Link:	ATRIPLA at DailyMed

See drug prices for ATRIPLA

Recent Clinical Trials for ATRIPLA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Willem Daniel Francois Venter	Phase 1
University of Cape Town	Phase 1
Yu-Jay Corp.	Phase 3

See all ATRIPLA clinical trials

Paragraph IV (Patent) Challenges for ATRIPLA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ATRIPLA	Tablets	efavirenz; emtricitabine; tenofovir disoproxil fumarate	600 mg/200 mg/300 mg	021937	1	2008-12-29

US Patents and Regulatory Information for ATRIPLA

ATRIPLA is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006		DISCN	Yes	No	9,018,192
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006		DISCN	Yes	No	9,545,414		Y
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006		DISCN	Yes	No	8,598,185		Y

Expired US Patents for ATRIPLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006	9,457,036
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006	6,703,396*PED
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006	9,744,181
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006	6,555,133
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006	6,043,230*PED
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006	5,210,085*PED
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006	6,238,695

International Patents for ATRIPLA

See the table below for patents covering ATRIPLA around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	T62566
World Intellectual Property Organization (WIPO)	9951239
Germany	602006004731
Japan	5398662
Bulgaria	99383
Germany	69809750
Hong Kong	1079122	Compositions and methods for combination antiviraltherapy

Supplementary Protection Certificates for ATRIPLA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0915894	C00915894/01	Switzerland		PRODUCT NAME: TENOFOVIR DISOPROXILFUMARAT + EMTRICITABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57316 21.03.2006
0915894	05C0032	France		PRODUCT NAME: TENOFOVIR DISOPROXIL FUMARATE; EMTRICITABINE; REGISTRATION NO/DATE: EU/1/04/305/001 20050221
0582455	SPC029/2000	Ireland		SPC029/2000: 20050912, EXPIRES: 20131119
0513200	C00513200/01	Switzerland		PRODUCT NAME: EMTRICITABINE; REGISTRATION NUMBER/DATE: SWISSMEDIC 56880 25.10.2004
0513200	7/2004	Austria		PRODUCT NAME: EMTRICITABIN; NAT. REGISTRATION NO/DATE: EU/1/03/261/001- EU/1/03/261/003 20031024; FIRST REGISTRATION: EU EU/1/03/261/003
0915894	08C0020	France		PRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213
0582455	CA 2001 00014	Denmark

Market Dynamics and Financial Trajectory for ATRIPLA

Last updated: February 19, 2026

What is ATRIPLA and its current market position?

ATRIPLA is a fixed-dose combination antiretroviral medication used to treat HIV-1 infection. It combines efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Approved by the FDA in 2012, ATRIPLA has historically been a primary treatment option due to its once-daily dosing and efficacy. Market presence is strong in North America, Western Europe, and select emerging markets, with annual sales peaking at approximately $1.6 billion in the late 2010s[1].

How has the market evolved since ATRIPLA’s introduction?

The HIV treatment landscape shifted with the development of newer antiretroviral therapies that offer improved safety profiles, fewer side effects, and simplified dosing. The arrival of single-tablet regimens such as Biktarvy (Gilead) and Genvoya (Gilead) has diminished ATRIPLA's market share.

In 2020, U.S. sales declined by roughly 20% year-over-year, trailing behind newer therapies, which gained a larger share in the HIV treatment market. Global sales also decreased, estimated at below $900 million for 2022, reflecting the migration to newer fixed-dose combinations.

What are the key market drivers affecting ATRIPLA's financial trajectory?

• Patent expiration: The primary patent for ATRIPLA expired in 2018 in the U.S. and Europe, exposing the drug to generic competition. Generic versions reduced prices and sales volume.

• Market competition: Newer therapies such as Biktarvy and Tivicay offer better safety profiles and once-daily dosing, appealing to both clinicians and patients.

• Pricing pressures: Gilead Sciences reduced prices for ATRIPLA to maintain market share post-generic entry; insurance coverage and government procurement policies favor newer, more profitable options.

• Safety and tolerability concerns: Issues like efavirenz-associated neuropsychiatric side effects prompted clinicians to shift toward alternatives with better tolerability.

• Regulatory initiatives: WHO and other health authorities promote the adoption of newer, more tolerable regimens, accelerating phased-out use of ATRIPLA.

How do patent protections and patent cliffs influence ATRIPLA’s revenue?

The patent expiration in 2018 led to increased generic competition, which causes prices to decline rapidly. As a result, Gilead’s revenue from ATRIPLA decreased significantly—by nearly 40% from 2017 to 2019 in various markets[2].

Gilead responded with price reductions and the promotion of newer fixed-dose combinations, which have marginally compensated for declining ATRIPLA revenue. Generic versions typically undercut branded prices by 60-80%, leading to a sharp decline in profit margins.

What is the outlook for ATRIPLA’s sales?

Sales are expected to decline further as global switch policies favor newer, better-tolerated therapies. By 2025, sales are projected to be below $300 million globally, mainly residual prescriptions in jurisdictions with slow adoption of newer regimens.

Gilead has shifted marketing focus toward other products and has almost phased out ATRIPLA from its core HIV portfolio in developed markets.

How are external factors shaping ATRIPLA’s market future?

• Regulatory guidance: Agencies emphasize the safety profile of HIV treatments. The use of efavirenz-based regimens like ATRIPLA diminishes in favor of integrase inhibitors.

• Pricing and reimbursement policies: Governments and insurers favor cost-effective, newer drugs, pressuring older branded therapies.

• Global health initiatives: Programs now emphasize access to newer drugs with better safety and adherence profiles. This accelerates the rollout of new medications over ATRIPLA.

What are key considerations for investors and R&D?

Investors should note that ATRIPLA’s revenue is in decline, with sustained erosion expected due to patent expiry and market preference shifts. R&D investments are increasingly directed toward next-generation therapies with improved safety profiles, such as long-acting injectables.

Gilead's pipeline includes long-acting cabotegravir and rilpivirine, indicating a strategic shift away from older oral regimens like ATRIPLA. These innovations could further diminish ATRIPLA’s market relevance.

Key Takeaways

• ATRIPLA faced significant revenue decline following patent expiration in 2018.
• Newer therapies with improved safety and adherence profiles have replaced ATRIPLA in most markets.
• Global sales are projected to fall below $300 million by 2025.
• Patent expiration, market competition, and regulatory preferences are primary drivers of future sales trajectory.
• Investment focus shifts toward long-acting injectable therapies and newer integrase inhibitors.

FAQs

1. Will ATRIPLA remain available in the market?
Yes, but sales will continue declining as generic versions dominate and newer therapies are adopted globally.

2. What are the main competitors to ATRIPLA?
Biktarvy (Gilead), Genvoya (Gilead), Dolutegravir-based regimens (ViiV Healthcare), and long-acting injectables like cabotegravir and rilpivirine.

3. How does patent expiration impact drug revenues?
It allows generics to enter the market, reducing branded drug prices and sales volumes, often causing revenue drops exceeding 50%.

4. Are there ongoing R&D efforts to replace ATRIPLA?
Yes. Gilead and other companies are developing long-acting injectables designed to improve adherence and safety.

5. What markets are least affected by ATRIPLA’s decline?
Countries with limited access to newer therapies or with slow regulatory adoption may continue to prescribe ATRIPLA longer.

---

References

[1] Gilead Sciences Inc. (2019). Annual Report. https://investors.gilead.com

[2] EvaluatePharma. (2020). HIV market overview. https://www.evaluate.com

[3] U.S. Food and Drug Administration (2012). FDA approval of ATRIPLA. https://www.fda.gov